[关键词]
[摘要]
视网膜静脉阻塞(RVO)是第二常见的致盲性视网膜血管病，其继发的黄斑水肿(ME)是导致患者视功能损害的重要原因。玻璃体内注射抗血管内皮生长因子(VEGF)药物为一线治疗手段，但存在需反复注射、部分患者无应答等问题。影像学和实验室生物标志物对RVO-ME的早期精准诊断、疾病发展预示及视力预后评估中发挥关键作用。文章系统综述近年来RVO-ME抗VEGF治疗预后相关影像学和实验室生物标志物的研究进展，涵盖中央视网膜厚度、椭圆体带完整性等影像学生物标志物，以及血清APLN、房水IL-6等实验室生物标志物。归纳不同标志物与抗VEGF治疗预后的关联，旨在为RVO-ME患者的早期精准评估、个体化治疗优化提供依据，具有重要临床参考价值。
[Key word]
[Abstract]
Retinal vein occlusion(RVO)is the second most common blinding retinal vascular disease, and its secondary macular edema(ME)is an important cause of visual function impairment in patients. Intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs serves as the first-line treatment, yet it is confronted with such issues as the need for repeated injections and non-response in some patients. Imaging and laboratory biomarkers play a crucial role in the early accurate diagnosis, prediction of disease progression, and evaluation of visual prognosis of RVO-ME. This study systematically reviews the research progress of imaging and laboratory biomarkers related to the prognosis of RVO-ME after anti-VEGF treatment in recent years, covering imaging biomarkers like central retinal thickness and ellipsoid zone integrity, as well as laboratory biomarkers such as serum APLN and aqueous humor IL-6. It summarizes the associations between different biomarkers and the prognosis of anti-VEGF therapy, aiming to provide a basis for the early accurate assessment and optimization of individualized treatment for RVO-ME patients, which holds significant clinical reference value.
[中图分类号]
[基金项目]
中国中医科学院眼科医院高水平中医医院项目(No.GSP5-83,GSP4-02-3); 国家自然科学基金资助项目(No.81603666); 首都临床特色应用研究重点研发项目(No.Z181100001718183); 中国中医科学院中央级公益性科研院所基本科研业务“优势病种-医院制剂-新药”研发专项(No.ZZ15-XY-PT-09); 中国中医科学院科技创新工程(No.CI2021A02606)
